drugset / Trial / NCT01806792

Post-menopausal Women Osteoporosis(Phase III)

NCT01806792

Phase 3 Completed 150 enrolled Hanlim Pharm. Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and the safety of Risedronate, cholecalciferol combination tablet in patients with Osteoporosis

Timeline

Start
2009-11
Primary completion
2010-08
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 30000 iu
Comparator Risedronate Small molecule 150 mg